RecruitingPhase 1NCT05147701

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Non-arteritic Ischemic Optic Neuropathy


Sponsor

The Foundation for Orthopaedics and Regenerative Medicine

Enrollment

20 participants

Start Date

Feb 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of non-arteritic ischemic optic neuropathy


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called AlloRx for people with diabetic retinopathy, eye diseases, and other related conditions. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAlloRx

cultured allogeneic adult umbilical cord derived mesenchymal stem cells


Locations(2)

Medical Surgical Associates Center

St John's, Antigua and Barbuda

Center for Investigation in Tissue Engineering and Cellular Therapy

Buenos Aires, Argentina

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05147701


Related Trials